Systematic Evaluation of Early Inhalation of Nitric Oxide for Prevention and Treatment of Bronchopulmonary Dysplasia in Premature Infants

Abstract

Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in premature infants, which seriously affects the quality of life of premature infants and may even lead to death of premature infants. At present, there is no unified opinion on the prevention and treatment of BPD, and the mechanism of its occurrence and development is not completely clear in clinical practice. Therefore, finding a better way to prevent and treat BPD is one of the hot spots in clinical practice. The safety of nitric oxide in premature infants with BPD is a focus of clinical attention, but its systematic evaluation has not been reported. In this study, meta-analysis method was used to analysis. The results demonstrated that there were no obvious differences in the incidence, survival, BPD-free survival, and mortality between the inhaled nitric oxide group (iNO group) and the placebo group. The common complications such as toxemia, necrotizing enterocolitis, and visual impairment between the iNO group and the placebo group were not obvious. This suggests that the use of NO to prevent BPD in premature infants has no obvious effect.